Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes

被引:5
|
作者
Chiang, Chieh [1 ]
Hsiao, Chin-Fu [1 ]
机构
[1] Natl Hlth Res Inst, Inst Populat Hlth Sci, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan
关键词
Multiregional clinical trial; interval estimation; sample size determination; Behrens-Fisher problem; consistency; SAMPLE-SIZE; REGIONS;
D O I
10.1177/0962280217751277
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Multiregional clinical trials have been accepted in recent years as a useful means of accelerating the development of new drugs and abridging their approval time. The statistical properties of multiregional clinical trials are being widely discussed. In practice, variance of a continuous response may be different from region to region, but it leads to the assessment of the efficacy response falling into a Behrens-Fisher problem-there is no exact testing or interval estimator for mean difference with unequal variances. As a solution, this study applies interval estimations of the efficacy response based on Howe's, Cochran-Cox's, and Satterthwaite's approximations, which have been shown to have well-controlled type I error rates. However, the traditional sample size determination cannot be applied to the interval estimators. The sample size determination to achieve a desired power based on these interval estimators is then presented. Moreover, the consistency criteria suggested by the Japanese Ministry of Health, Labour and Welfare guidance to decide whether the overall results from the multiregional clinical trial obtained via the proposed interval estimation were also applied. A real example is used to illustrate the proposed method. The results of simulation studies indicate that the proposed method can correctly determine the required sample size and evaluate the assurance probability of the consistency criteria.
引用
收藏
页码:2179 / 2195
页数:17
相关论文
共 50 条
  • [1] Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances
    Wu, Yuh-Jenn
    Cheng, Yu-Chieh
    Chiang, Chieh
    Cheng, Li-Hsueh
    Liu, Ching-Ti
    Hsiao, Chin-Fu
    [J]. STATISTICS IN MEDICINE, 2022, 41 (01) : 87 - 107
  • [2] Cautionary note on regional consistency evaluation in multiregional clinical trials with binary outcomes
    Homma, Gosuke
    [J]. PHARMACEUTICAL STATISTICS, 2024, 23 (03) : 385 - 398
  • [3] STATISTICAL CONSIDERATIONS ON DESIGN AND ANALYSIS OF BRIDGING AND MULTIREGIONAL CLINICAL TRIALS
    Tsong, Yi
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1078 - 1080
  • [4] Integration of patient-reported outcomes in multiregional confirmatory clinical trials
    Gnanasakthy, Ari
    DeMuro, Carla
    Boulton, Caroline
    [J]. CONTEMPORARY CLINICAL TRIALS, 2013, 35 (01) : 62 - 69
  • [5] EVALUATION OF THE USE OF SURROGATE OUTCOMES IN ONCOLOGY CLINICAL TRIALS
    Sharma, R.
    Goulding, R.
    Franklin, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S333 - S333
  • [6] DESIGN AND EVALUATION OF MULTIREGIONAL TRIALS WITH HETEROGENEOUS TREATMENT EFFECT ACROSS REGIONS
    Chen, Chi-Tian
    Hung, H. M. James
    Hsiao, Chin-Fu
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1037 - 1050
  • [7] ESTIMATIONS OF RESOURCE USE, COSTS, CLINICAL AND EPIDEMIOLOGICAL OUTCOMES OF CONTINUOUS AND INTERMITTENT RENAL REPLACEMENT THERAPIES
    Garay, O. U.
    Palacios, A.
    Tapia-Lopez, E.
    Hernandez-Vasquez, A.
    Garcia Marti, S.
    Pichon-Riviere, A.
    Augustovski, F.
    Bardach, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A866 - A866
  • [8] DESIGN AND ANALYSIS ISSUES OF MULTIREGIONAL CLINICAL TRIALS WITH DIFFERENT REGIONAL PRIMARY ENDPOINTS
    Tsou, Hsiao-Hui
    Tsong, Yi
    Chang, Wan-Jung
    Dong, Xiaoyu
    Hsiao, Chin-Fu
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1051 - 1059
  • [9] An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials
    Huang, Yufen
    Chang, Wan-Jung
    Hsiao, Chin-Fu
    [J]. PHARMACEUTICAL STATISTICS, 2013, 12 (02) : 59 - 64
  • [10] Power estimations for non-primary outcomes in randomised clinical trials
    Jakobsen, Janus Christian
    Ovesen, Christian
    Winkel, Per
    Hilden, Jorgen
    Gluud, Christian
    Wetterslev, Jorn
    [J]. BMJ OPEN, 2019, 9 (06):